LONDON, UK / ACCESSWIRE / October 10, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Cantel Medical Corp. (NYSE: CMD), which can be viewed by registering at http://protraderdaily.com/optin/'symbol=CMD, following the Company's announcement of its financial results on September 28, 2017, for the fourth quarter of the fiscal year 2017. Cantel Medical's net revenue increased 14.8% on a y-o-y basis. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:
http://protraderdaily.com/register/
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on CMD. With the links below you can directly download the report of your stock of interest free of charge at:
http://protraderdaily.com/optin/'symbol=CMD
Earnings Reviewed
For the three months ended July 31, 2017, Cantel Medical's net revenue increased 14.8% to $205.50 million from $179.00 million in Q4 FY16, due to an organic revenue growth of 9.2% and a positive acquisition impact. The net revenue figures surpassed analysts' expectations of $200.32 million.
During FY17, Cantel Medical's net revenue increased 15.8% to $770.16 million from $664.76 million in FY16.
During Q4 FY17, Cantel Medical's gross profit increased 14.5% to $97.73 million from $85.33 million in Q4 FY16. For the reported quarter, the Company's gross margin decreased 10 basis points to 47.5% of revenue from 47.6% of revenue in Q4 FY16.
During Q4 FY17, Cantel Medical's earnings before interest, tax, depreciation, and amortization (EBITDA) increased 14.2% to $40.35 million from $35.31 million in Q4 FY16. For the reported quarter, the Company's adjusted EBITDA increased 13.1% to $42.56 million from $37.63 million in Q4 FY16. During Q4 FY17, the Company's adjusted EBITDA margin decreased 30 basis points to 20.7% of revenue from 21.0% of revenue in Q4 FY16.
During Q4 FY17, Cantel Medical's selling expenses increased 9.6% to $30.80 million from $28.10 million in Q4 FY16. During Q4 FY17, the Company's G&A expenses increased 28.5% to $34.60 million from $26.91 million in the same period of last year. For the reported quarter, the Company's R&D expenses increased 11.7% to $5.04 million from $4.51 million in Q4 FY16.
During Q4 FY17, Cantel Medical's operating income increased 5.6% to $27.29 million from $25.82 million in Q4 FY16. For the reported quarter, the Company's operating margin decreased 120 basis points to 13.2% of revenue from 14.4% of revenue in Q4 FY16.
During FY17, Cantel Medical's operating income increased 13.5% to $110.41 million from $97.25 million in FY16. During FY17, the Company's operating margin decreased 30 basis points to 14.3% of revenue from 14.6% of revenue in FY16.
During Q4 FY17, Cantel Medical's net income increased 4.3% to $17.00 million on a y-o-y basis from $16.29 million in Q4 FY16. For the reported quarter, the Company's adjusted net income increased 11.5% to $22.49 million on a y-o-y basis from $20.16 million in Q4 FY16. For the reported quarter, the Company's diluted earnings per share (EPS) increased 5.1% to $0.41 on a y-o-y basis from $0.39 in Q4 FY16. During Q4 FY17, Cantel Medical's adjusted diluted EPS increased 12.5% to $0.54 on a y-o-y basis from $0.48 in Q4 FY16. The adjusted diluted EPS was at par with analysts' expectations of $0.54.
During FY17, Cantel Medical's net income increased 19.0% to $71.38 million from $59.95 million in FY16. During FY17, the Company's adjusted net income increased 18.9% to $86.74 million from $72.94 million in FY16. During FY17, the Company's diluted EPS increased 18.7% to $1.71 from $1.44 in FY16. During FY17, Cantel Medical's adjusted diluted EPS increased 18.8% to $2.08 from $1.75 in FY16.
Segment Results
During Q4 FY17, Cantel Medical's Endoscopy segment's revenue growth was 13.9% and organic revenue growth was 9.7%. For the reported quarter, the Company's Water Purification and Filtration segment's revenue growth was 13.7%, and Healthcare Disposables segment's revenue growth was 23.0%.
Balance Sheet
As on July 31, 2017, Cantel Medical's cash and cash equivalents increased 28.9% to $36.58 million from $28.37 million in Q4 FY16.
During Q4 FY17, the Company's net accounts receivables increased 18.5% to $110.66 million from $93.33 million in Q4 FY16.
For the reported quarter, Cantel Medical's net inventories increased 7.9% to $98.72 million from $91.49 million in Q4 FY16.
For the reported quarter, the Company's long-term debt increased 8.6% to $126.00 million from $116.00 million in Q4 FY16.
Stock Performance
At the closing bell, on Monday, October 09, 2017, Cantel Medical's stock fell slightly by 0.84%, ending the trading session at $96.46. A total volume of 112.27 thousand shares have exchanged hands. The Company's stock price soared 28.37% in the last three months, 31.65% in the past six months, and 22.69% in the previous twelve months. Moreover, the stock surged 22.49% since the start of the year. The stock has a dividend yield of 0.15% and currently has a market cap of $4.11 billion.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@protraderdaily.com
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily
